Rezafungin acetate is under clinical development by Cidara Therapeutics and currently in the Phase III and Pre-Registration in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Rezafungin acetate’s likelihood of approval (LoA) and phase transition for Systemic Candidiasis took place on 22 Sep 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Rezafungin acetate Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Rezafungin acetate overview

Rezafungin acetate is under development for the treatment and prophylaxis of aspergillosis in COVID-19 patients, pneumocystis pneumonia,Trichophyton mentagrophytes, Trichophyton rubrum, Microsporum gypseum, systemic candida infections including candidemia and related cases of invasive candidiasis. The drug candidate is a long acting echinocandin. It is administered intravaginally, subcutaneously and intravenously as a solution and a gel. The drug candidate was under development for the treatment of vulvovaginal candidiasis.

Cidara Therapeutics overview

Cidara Therapeutics (Cidara) formerly K2 Therapeutics is a biotechnology company. The company discovers, develops and commercializes novel anti-infectives including immunotherapies. Its pipeline products include rezafungin for the treatment of invasive fungal disease and CD388 for treating influenza. Cidara is investigating RSV AVC program for the treatment of respiratory syncytial virus (RSV), HIV AVC for human immunodeficiency viruses (HIV), CoV AVC for pan coronavirus. The company’s proprietary Cloudbreak, an antiviral platform for the fight against life-threatening infectious diseases that provides potent antiviral activity and immune system engagement in a single molecule. Cidara is headquartered in San Diego, California, the US.

Quick View Rezafungin acetate LOA Data

Report Segments
  • Innovator
Drug Name
  • Rezafungin acetate
Administration Pathway
  • Intravenous
  • Subcutaneous
  • Vaginal
Therapeutic Areas
  • Infectious Disease
Key Developers
Highest Development Stage
  • Pre-Registration

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.